Sorrento, Korea's Cha setting up global JV

Sorrento Therapeutics Inc. (NASDAQ:SRNE) and Cha Bio&Diostech Co. Ltd. (KOSDAQ:085660) are forming a JV to develop and commercialize chimeric antigen receptor (CAR)-modified cell therapies globally, excluding Greater China.

The JV will develop CAR therapies based on Cha's activated killer cell (AKC) technology, including five Sorrento CAR therapies with which it will be combined. The AKC technology derives natural killer (NK) cells from a patient's peripheral blood. ...